studies

breast cancer (BC), anti-PD-(L)1 vs. placebo plus SoC, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpassion-031 (all population), 2020 0.69 [0.25; 1.89] KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05] KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03] KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96] 0.85[0.76; 0.95]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 202040%2,139lownot evaluable progression or deaths (PFS)detailed resultsKEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97] KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91] KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88] 0.77[0.68; 0.86]KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 202030%1,806lownot evaluable events or deaths (EFS)detailed resultsIMpassion-031 (all population), 2020 0.76 [0.40; 1.44] 0.76[0.40; 1.44]IMpassion-031 (all population), 202010%333NAnot evaluable objective responses (ORR)detailed resultsKEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33] KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80] KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60] 0.79[0.23; 2.73]KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020397%1,806lownot evaluable pCR detailed resultsIMpassion-031 (all population), 2020 1.95 [1.26; 3.01] IMpassion-031 (PDL1>1%), 2020 2.23 [1.16; 4.30] 2.03[1.41; 2.92]IMpassion-031 (all population), 2020, IMpassion-031 (PDL1>1%), 202020%487lownot evaluable AE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.49 [0.02; 14.69] KEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87] 1.14[0.39; 3.33]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.10 [0.71; 1.72] KEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76] 1.20[0.92; 1.57]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable AE leading to death (grade 5)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpassion-031 (all population), 2020 1.18 [0.70; 2.01] 1.18[0.70; 2.01]IMpassion-031 (all population), 202010%331NAnot evaluable SAE (any grade)detailed resultsIMpassion-031 (all population), 2020 2.00 [1.20; 3.36] 2.00[1.20; 3.36]IMpassion-031 (all population), 202010%331NAnot evaluable STRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 1.58 [0.91; 2.75] 1.58[0.91; 2.75]IMpassion-031 (all population), 202010%331NAnot evaluable TRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.98 [0.14; 7.05] KEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70] 1.30[0.68; 2.51]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.15 [0.74; 1.77] KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44] 1.09[0.85; 1.40]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable TRAE leading to death (grade 5)detailed resultsKEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 2.00[0.09; 44.58]KEYNOTE-355 (all population), 202010%843NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51] 0.83[0.20; 3.51]KEYNOTE-355 (all population), 202010%843NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71] 1.15[0.77; 1.71]KEYNOTE-355 (all population), 202010%843NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 2.02[0.20; 20.01]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82] 1.15[0.47; 2.82]KEYNOTE-355 (all population), 202010%843NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90] 1.01[0.08; 13.16]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.54[0.14; 17.62]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48] 1.29[0.67; 2.48]KEYNOTE-355 (all population), 202010%843NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19] 0.83[0.58; 1.19]KEYNOTE-355 (all population), 202010%843NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69] 1.13[0.34; 3.69]KEYNOTE-355 (all population), 202010%843NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36] 0.99[0.73; 1.36]KEYNOTE-355 (all population), 202010%843NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78] 3.84[0.42; 34.72]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable Rash TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.32; 3.23] 1.02[0.32; 3.23]IMpassion-031 (all population), 202010%331NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64] 4.60[0.46; 46.07]IMpassion-031 (all population), 2020, KEYNOTE-355 (all population), 202020%1,174lownot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Anaemia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.21 [0.54; 2.69] 1.21[0.54; 2.69]IMpassion-031 (all population), 202010%331NAnot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Asthenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.54 [0.25; 9.32] 1.54[0.25; 9.32]IMpassion-031 (all population), 202010%331NAnot evaluable Back pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Cough AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.15 [0.46; 37.53] 4.15[0.46; 37.53]IMpassion-031 (all population), 202010%331NAnot evaluable Dry skin AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.14; 7.32] 1.02[0.14; 7.32]IMpassion-031 (all population), 202010%331NAnot evaluable Epistaxis AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.23 [0.37; 4.11] 1.23[0.37; 4.11]IMpassion-031 (all population), 202010%331NAnot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.25 [0.61; 2.57] 1.25[0.61; 2.57]IMpassion-031 (all population), 202010%331NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Hypertension AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.84 [0.35; 2.00] 0.84[0.35; 2.00]IMpassion-031 (all population), 202010%331NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.44 [0.62; 9.59] 2.44[0.62; 9.59]IMpassion-031 (all population), 202010%331NAnot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.91 [0.36; 2.30] 0.91[0.36; 2.30]IMpassion-031 (all population), 202010%331NAnot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.86 [0.76; 4.55] 1.86[0.76; 4.55]IMpassion-031 (all population), 202010%331NAnot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Myalgia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Nausea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.28 [0.06; 1.38] 0.28[0.06; 1.38]IMpassion-031 (all population), 202010%331NAnot evaluable Neutropenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.10 [0.65; 1.84] 1.10[0.65; 1.84]IMpassion-031 (all population), 202010%331NAnot evaluable Oropharyngeal pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Paraesthesia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral neuropathy AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.40 [0.08; 2.09] 0.40[0.08; 2.09]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral oedema AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Peripheral sensory neuropathy AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.28 [0.34; 4.86] 1.28[0.34; 4.86]IMpassion-031 (all population), 202010%331NAnot evaluable Pruritus AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.25 [0.03; 2.26] 0.25[0.03; 2.26]IMpassion-031 (all population), 202010%331NAnot evaluable Pyrexia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.11 [0.18; 91.86] 4.11[0.18; 91.86]IMpassion-031 (all population), 202010%331NAnot evaluable Rash AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.15 [0.46; 37.53] 4.15[0.46; 37.53]IMpassion-031 (all population), 202010%331NAnot evaluable Stomatitis AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 6.20 [0.31; 124.85] 6.20[0.31; 124.85]IMpassion-031 (all population), 202010%331NAnot evaluable Vomiting AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.05 [0.18; 22.82] 2.05[0.18; 22.82]IMpassion-031 (all population), 202010%331NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-26 21:23 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons